By joint analysis of relapse-gained and diagnostic mutations, including the extension cohort, we found that BCP-ALL patients with EBF1 or AFF3 mutations and T-ALL patients with ARID1A mutations relapsed frequently. Here, ARID1A is linked to acute lymphoblastic leukemia.